

Datasheet: MCA2537B

Description:	MOUSE ANTI HUMAN CD16:Biotin		
Specificity:	CD16		
Other names:	FcRIII		
Format:	Biotin		
Product Type:	Monoclonal Antibody		
Clone:	DJ130c		
Isotype:	lgG1		
Quantity:	0.1 mg		

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
Flow Cytometry	•			Neat - 1/10

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

Target Species	Human
Species Cross Reactivity	Reacts with: Macaque N.B. Antibody reactivity and working conditions may vary between species. Cross reactivity is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information.
Product Form	Purified IgG conjugated to Biotin - liquid
Preparation	Purified IgG prepared by affinity chromatography on Protein A from tissue culture supernatant
Buffer Solution	Phosphate buffered saline
Preservative Stabilisers	0.09% Sodium Azide (NaN ₃) 1% Bovine Serum Albumin

Approx.	Protein
Concent	rations

IgG concentration 0.1mg/ml

External Database Links

UniProt:

P08637 Related reagents
O75015 Related reagents

Entrez Gene:

2214 FCGR3A Related reagents2215 FCGR3B Related reagents

Synonyms

CD16A, CD16B, FCG3, FCGR3, IGFR3

RRID

AB_877458

Specificity

Mouse anti Human CD16 antibody, clone DJ130c recognizes human CD16, also known as Low affinity immunoglobulin gamma Fc region receptor III-A or Fc-gamma RIIIa. CD16a is a 254 amino acid ~50-65 kDa single pass type 1 transmembrane glycoprotein bearing two Ig-Iike C2 type domains. CD16 exists as a transmembranous form (Fc gammaRIIIA, or CD16A) and a glycosyl phosphatidylinositol (GPI) anchored form, Fc gammaRIIIB, or CD16B (Scallon et al. 1989). CD16A is expressed by NK cells, some T cells, and macrophages, whereas CD16B is primarily expressed by granulocytes (Ravetch and Perussia 1989). In addition, CD16B exists as two allelic variants NA1 and NA2. DJ130c recognizes all polymorphonuclear cells irrespective of their NA phenotype.

Mouse anti Human CD16 antibody, clone DJ130c recognizes an epitope in the first membrane-distal domain of CD16, recognizes both CD16a and CD16b and has been demonstrated to cross-react with CD16 from rhesus macaques, *Macaca mulatta* (Xu et al. 2012)

Flow Cytometry

Use 10ul of the suggested working dilution to label 1x10⁶ cells in 100ul.

References

- 1. Schmidt, R.E. (1993) CD16 cluster workshop report. In Leucocyte Typing V: White cell differentiation antigens, Vol.1. Edited by Schlossman, S.F. *et al.* Oxford University Press. p805 806.
- 2. Kakko, T. *et al.* (2011) Inflammatory effects of blood leukocytes: association with vascular function in neuropeptide Y proline 7-genotyped type 2 diabetes patients. <u>Diab Vasc Dis Res.</u> 8: 221-8.
- 3. Shantsila, E. *et al.* (2012) Fibrinolytic status in acute coronary syndromes: evidence of differences in relation to clinical features and pathophysiological pathways. <u>Thromb</u> Haemost. 108: 32-40.
- 4. Shantsila, E. *et al.* (2011) Immunophenotypic characterization of human monocyte subsets: possible implications for cardiovascular disease pathophysiology. <u>J Thromb</u> Haemost. 9: 1056-66.
- 5. Tapp, L.D. *et al.* (2012) The CD14++CD16+ monocyte subset and monocyte-platelet interactions in patients with ST-elevation myocardial infarction. <u>J Thromb Haemost. 10:</u>

1231-41.

- 6. Ambarus, C.A. *et al.* (2012) Intimal lining layer macrophages but not synovial sublining macrophages display an IL-10 polarized-like phenotype in chronic synovitis. <u>Arthritis Res Ther. 14: R74.</u>
- 7. Ambarus, C.A. *et al.* (2012) Systematic validation of specific phenotypic markers for in vitro polarized human macrophages. <u>J Immunol Methods</u>. 375: 196-206.
- 8. Ambarus, C.A. *et al.* (2012) Soluble immune complexes shift the TLR-induced cytokine production of distinct polarized human macrophage subsets towards IL-10. <u>PLoS One. 7:</u> e35994.
- 9. Shantsila, E. *et al.* (2012) The effects of exercise and diurnal variation on monocyte subsets and monocyte-platelet aggregates. Eur J Clin Invest. 42: 832-9.
- 10. Chehadeh. W. *et al.* (2009) Antibody-mediated opsonization of red blood cells in parvovirus B19 infection. Virology. 390: 56-63.
- 11. Wrigley, B.J. *et al.* (2013) Increased formation of monocyte-platelet aggregates in ischemic heart failure. <u>Circ Heart Fail. 6: 127-35.</u>
- 12. Jaipersad, A.S. *et al.* (2014) Expression of monocyte subsets and angiogenic markers in relation to carotid plaque neovascularization in patients with pre-existing coronary artery disease and carotid stenosis. Ann Med. 11: 1-9.
- 13. Shantsila, E. *et al.* (2015) Free Light Chains in patients with acute coronary syndromes: Relationships to inflammation and renal function. <u>Int J Cardiol. 185: 322-7.</u>
- 14. Wrigley, B.J. *et al.* (2013) Increased formation of monocyte-platelet aggregates in ischemic heart failure. <u>Circ Heart Fail. 6 (1): 127-35.</u>
- 15. Romee R *et al.* (2013) NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17). Blood. 121 (18): 3599-608.
- 16. Sousa, S. *et al.* (2015) Human breast cancer cells educate macrophages toward the M2 activation status. <u>Breast Cancer Res. 17: 101.</u>
- 17. Shantsila, E. *et al.* (2019) Mon2 predicts poor outcome in ST-elevation myocardial infarction. J Intern Med. 285 (3): 301-16.
- 18. Brown, R.A. *et al.* (2018) Impact of Mon2 monocyte-platelet aggregates on human coronary artery disease. Eur J Clin Invest. 48 (5): e12911.
- 19. Nakajima-Kato, Y. *et al.* (2023) A novel monoclonal antibody with improved FcγR blocking ability demonstrated non-inferior efficacy compared to IVIG in cynomolgus monkey ITP model at considerably lower dose. <u>Clin Exp Immunol. 211 (1): 23-30.</u>

Storage

This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.

Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.

Guarantee	12 months from date of despatch		
Health And Safety Information	Material Safety Datasheet documentation #10041 available at: https://www.bio-rad-antibodies.com/SDS/MCA2537B 10041		
Regulatory	For research purposes only		

Related Products

Recommended Useful Reagents

HUMAN SEROBLOCK (BUF070A) HUMAN SEROBLOCK (BUF070B)

 North & South
 Tel: +1 800 265 7376
 Worldwide
 Tel: +44 (0)1865 852 700
 Europe
 Tel: +49 (0) 89 8090 95 21

 America
 Fax: +1 919 878 3751
 Fax: +44 (0)1865 852 739
 Fax: +49 (0) 89 8090 95 50

 $\textbf{Email: antibody_sales_us@bio-rad.com} \\ \textbf{Email: antibody_sales_uk@bio-rad.com} \\ \textbf{Email: antibody_sales_uk@b$

To find a batch/lot specific datasheet for this product, please use our online search tool at: bio-rad-antibodies.com/datasheets 'M437753:250318'

Printed on 18 Mar 2025

© 2025 Bio-Rad Laboratories Inc | Legal | Imprint